Plain-English translation of NCT06753994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a wearable sensor that continuously monitors ketone levels in people with type 1 diabetes who are taking empagliflozin, a medication that helps lower blood sugar. Empagliflozin can sometimes increase ketone levels, which may be dangerous at high levels. By watching ketone levels in real time, doctors hope to use this medication safely and help protect your kidneys while avoiding complications.
Currently, checking ketone levels requires finger-prick blood tests, which often detect problems too late to prevent a serious condition called diabetic ketoacidosis. This trial wants to see if real-time ketone monitoring can catch unsafe levels early and allow for quick action, so the new treatment can be used at higher, more protective doses without risk.
You likely qualify if…
You likely don't qualify if…
You would wear a continuous ketone monitor for about 4 weeks to establish a baseline, then start the medication at a low dose for 4 weeks while continuing to wear the sensor. The dose would increase to a higher level for 9 weeks, during which you would continue monitoring. You'd also participate in an exercise study twice during the trial, and some participants may try a lower-carbohydrate diet during the final week. Throughout, you'll come in for check-ups and continue your regular insulin therapy and glucose monitoring.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Canada